Publications by authors named "Christopher Fegan"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,087,069

Total Likes

62,257

Extended Reach

5,008,976

Social Features

505
S
Social deprivation independently impacts clinical outcomes in patients with chronic lymphocytic leukemia.
Gregory Fegan, Daniel Tod, Abigail Downing, Nagah Elmusharaf, Christopher Pepper, Christopher Fegan

Haematologica· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Ross A Jackson, Robert G Britton, Sandrine Jayne, Susann Lehmann, Caroline M Cowley, Christopher Fegan

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Infection.
Valerie B O'Donnell, David Thomas, Richard Stanton, Jean-Yves Maillard, Robert C Murphy, Christopher Fegan

Function (Oxf)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma.
Thomas A Burley, Emma Kennedy, Georgia Broad, Melanie Boyd, David Li, Christopher Fegan

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia.
Thomas A Burley, Andrew Hesketh, Giselda Bucca, Emma Kennedy, Eleni E Ladikou, Christopher Fegan

Cancers (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length.
Eileen M Boyle, Louis Williams, Patrick Blaney, Cody Ashby, Michael Bauer, Christopher D Fegan

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Andrea G S Pepper, Antonella Zucchetto, Kevin Norris, Erika Tissino, Jerry Polesel, Christopher D Fegan

Leukemia· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
Franck Morschhauser, Martin J S Dyer, Harriet S Walter, Alexey V Danilov, Loic Ysebaert, Christopher Fegan

Leukemia· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
Toby A Eyre, Gavin Preston, Huseini Kagdi, Amin Islam, Toby Nicholson, Christopher Fegan

Br J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
Emma Kennedy, Eve Coulter, Emma Halliwell, Nuria Profitos-Peleja, Elisabeth Walsby, Christopher D Fegan

Blood· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-κB activity and synergise with bortezomib and ibrutinib in hematological cancers.
Thomas Lewis, David B Corcoran, David E Thurston, Peter J Giles, Kevin Ashelford, Christopher D Fegan

Haematologica· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens.
Stuart J Moat, Wioleta M Zelek, Emily Carne, Mark J Ponsford, Kathryn Bramhall, Christopher Fegan

Ann Clin Biochem· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.
Wei-Yu Lin, Sarah E Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Christopher Fegan

Nat Commun· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial.
Andrew R Pettitt, Richard Jackson, Silvia Cicconi, Fotis Polydoros, Christina Yap, Christopher Fegan

Haematologica· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.
Wioleta M Zelek, Jade Cole, Mark J Ponsford, Richard A Harrison, Ben E Schroeder, Christopher Fegan

Am J Respir Crit Care Med· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.
Jared A Cohen, Francesca Maria Rossi, Antonella Zucchetto, Riccardo Bomben, Lodovico Terzi-di-Bergamo, Christopher D Fegan

Haematologica· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Alexey V Danilov, Charles Herbaux, Harriet S Walter, Peter Hillmen, Simon A Rule, Christopher D Fegan

Clin Cancer Res· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Simon A Rule, Guillaume Cartron, Christopher Fegan, Franck Morschhauser, Lingling Han

Leukemia· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical utility of telomere length measurements in cancer.
Chris Pepper, Kevin Norris, Christopher Fegan

Curr Opin Genet Dev· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study.
Peter Hillmen, Andy C Rawstron, Kristian Brock, Samuel Muñoz-Vicente, Francesca J Yates, Christopher Fegan

J Clin Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telomere length predicts for outcome to FCR chemotherapy in CLL.
Kevin Norris, Peter Hillmen, Andrew Rawstron, Robert Hills, Duncan M Baird, Christopher D Fegan

Leukemia· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs).
David B Corcoran, Thomas Lewis, Kazi S Nahar, Shirin Jamshidi, Christopher Fegan

J Med Chem· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology Guideline.
Anna H Schuh, Nilima Parry-Jones, Niamh Appleby, Adrian Bloor, Claire E Dearden, Christopher Fegan

Br J Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis